Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Pharmacia & Upjohn launches Aromasin breast cancer therapy in the U.S.

Jan. 24, 2000

New findings enhance validity of preclinical models for evaluating LHRH peptide conjugates

Jan. 24, 2000

Takeda reveals new GnRH antagonists in recently issued patent

Jan. 24, 2000

Immunomedics' bispecific fusion proteins covered by U.S. patent

Jan. 24, 2000

NCI to initiate phase III trial of Neovastat in the U.S. and Canada

Jan. 24, 2000

German colorectal cancer patients have new treatment option: Sanofi-Synthelabo's Eloxatin

Jan. 21, 2000

Human Genome Sciences initiates phase II clinical trial of repifermin for mucositis

Jan. 21, 2000

Pharmacia & Upjohn and Geron extend telomerase collaboration

Jan. 21, 2000

Myriad Genetics patent covers p19 therapeutic and diagnostic development

Jan. 20, 2000

Joint venture formed by Ribozyme and Elan to develop anticancer ribozyme product

Jan. 20, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...